Ealing Pharmaceuticals Lianhua Qingdian capsule overseas "circle of friends" and add a friend.
November 5, Ealing Pharmaceuticals announced that the company recently received by the Eurasian Economic Union member states authorized institutions - "to academician S.H. Avdalbekyan named National Institute of Health" closed joint-stock companies under the The document of approval for registration of dietary supplements issued by the Laboratory of Healthcare Testing of JSC "National Institute of Health named after Academician S.H. Avdalbekyan", an authorized institution of the Eurasian Economic Union member states, approves the registration of the company's pharmaceutical product Lianhua Qingdian Capsule in compliance with the Russian standards for dietary supplements.
According to the company's three-quarterly report shows that in the first three quarters of 2020, Ealing Pharmaceuticals Lianhua Qingdian products to achieve operating income of 2.871 billion yuan, accounting for 44.52% of the company's total operating income. 2019, Ealing Pharmaceuticals Lianhua Qingdian products to achieve operating income of 1.703 billion yuan, accounting for 29.24% of the company's total operating income. 2020 first three quarters Lianhua Qingdian product revenue exceeded last year. Revenue exceeded last year's full year.
Marketed in 15 countries
Lianhua Qingdian is the leading product of Ealing Pharmaceuticals, the national essential drugs catalog and the national health insurance catalog (Class A) varieties, which is mainly used for the treatment of colds and influenza-related diseases. Lianhua Qingdian has been included in the diagnosis and treatment programs for cold and flu related diseases by the National Health Commission and the State Administration of Traditional Chinese Medicine for many times.
In 2020, Lianhua Qingdian Capsule/Particle was listed as a recommended medicine in the "New Coronavirus Pneumonia Diagnosis and Treatment Program" (Trial 4th/5th/6th/7th/8th Edition) jointly issued by the National Health and Health Commission and the State Administration of Traditional Chinese Medicine. 2020, April 12, 2020, the State Drug Administration approved the Lianhua Qingdian Capsule/Particle, on the basis of the original approved indications, to add The new indication of "new coronavirus pneumonia light, ordinary type".
Up to now, in addition to Russia, Lianhua Qingdian capsule has been in Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, Laos, Kyrgyzstan, the Philippines, Kuwait, Mauritius, Uganda and other countries, respectively, under the "proprietary Chinese medicine", "Pharmaceuticals", "Botanicals", "Natural Health Products", "Food Supplements", "Modern Botanicals", "Natural Medicines", etc..
Ealing Pharmaceuticals said, the Lianhua Qingdian capsule obtained the Russian dietary supplement registration approval, marking the company has the qualification to sell the product in the Russian market in the capacity of dietary supplements, the company's expansion of the overseas market has a positive impact.
Wu Rui said: "In terms of overseas business, the company has set up an international trade center, which is fully responsible for the sales of products in overseas markets. At present, Lianhua Qingdian products have been registered before the overall sales growth in 14 countries, at the same time, the company is also synchronized in the Middle East, Africa, Latin America and other countries to actively promote the registration work, and continue to actively promote the overseas registration and sales of Lianhua Qingdian products, in order to further expand the product's overseas market share to make positive efforts."
Brand awareness continues to improve
According to Ealing Pharmaceuticals previously released the third quarterly report shows that in the first three quarters, the company achieved a total operating income of 6.447 billion yuan, an increase of 48.31% year-on-year; to achieve net profit attributable to shareholders of the parent company of 1.016 billion yuan, an increase of 76.74% year-on-year; and to achieve a non-taxed net profit of 982 million yuan, an increase of 76.74% year-on-year. Net profit of 982 million yuan, an increase of 81.95%. In this way, the total operating income and net profit attributable to mother of Ealing Pharmaceuticals in the first three quarters have exceeded the full year of 2019.
Quarter by quarter, from the first quarter to the third quarter of 2020, Ealing Pharmaceuticals realized total operating income of 2.334 billion yuan, 2.153 billion yuan and 1.960 billion yuan in a single quarter, up 50.56%, 50.13% and 43.84% year-on-year, respectively; and realized non-returned net profit of 438 million yuan, 276 million yuan and 302 million yuan, up 51.88%, 66.02%, 151.25%.
For the growth in performance, Wu Rui said: "First, due to the Lianhua Qingdao and Ealing Pharmaceuticals brand awareness has increased significantly, Lianhua Qingdao products in the third quarter of sales revenue is still more than 50% growth; second, the company's cardio-cerebral vascular series of products to restore the growth of further increase in the trend of cardiac and cerebrovascular products, Tongxinluo and ginseng pine heart to achieve double-digit growth, Qidanemerosa hebecarpa hebecarpa heart to achieve Year-on-year increase of nearly 40%; Third, the company continues to promote the optimization and upgrading of the marketing system, the effect of the measures began to appear, the company's main varieties of the third quarter of the single-quarter sales revenue have shown a good growth trend."
Talking about the performance of cardiovascular products in 2020, Wu Rui said: "The company's cardiovascular products show quarter by quarter growth trend. In the first quarter of this year, by the traffic control, medical resources to fever clinic tilt, the company's production line to Lianhua plague tilt and other factors, cardiovascular and cerebrovascular products, sales revenue year-on-year a slight decline; the second quarter, the domestic epidemic is under better control, the company won the first prize of the National Science and Technology Progress for the three cardiovascular and cerebrovascular products to enhance the influence of market role has been initially seen, coupled with Lianhua plague products to drive the brand awareness of the Yiling Pharmaceuticals and other products to enhance the brand awareness, and other products to enhance the brand awareness. and other products to enhance brand awareness, the company's marketing system optimization, sales force expansion, covering the blank market, the product began to line, for different terminals to develop different sales strategies and other measures from the second quarter began to show the effect of cardio-cerebral vascular product sales revenue year-on-year to achieve more than 10% growth; the third quarter of the quarter, cardio-cerebral vascular series of products to restore growth trend further increased. "
In addition, Wu Rui talked about: "the company set up in the medical terminal Lianhua Division, for the future to maintain a high market share to lay a solid foundation. Moreover, the fall and winter seasons are generally high season of influenza and other respiratory diseases, but also the peak season for sales of Lianhua Qingdian products, the company expects Lianhua Qingdian in the fourth quarter can still continue to higher growth trend."
In the view of Pan and Lin, "the three-quarter Ealing Pharmaceuticals performance surge, indicating that Ealing Pharmaceuticals has seized the market pain point, its business classification, the demand for anti-flu drugs has increased substantially, such drugs to Lianhua Qingdian as the leading. In the long term, the field of drugs has entered the stage of R & D arms race, in the context of band purchasing, Ealing Pharmaceuticals also need to further take the road of R & D innovation, more money into the future."